Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 19/20 | 1.00 |
| ▸ | STAT6 | P42226 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 6-Benzylthioinosine SCHEMBL15427008 | 1.00 | SLC29A1 (1.00) | SLC29A1STAT6 | |
| 6-Benzylthioinosine SCHEMBL7617372 | 1.00 | SLC29A1 (1.00) | SLC29A1STAT6 | |
| 6-Benzylthioinosine SCHEMBL7617380 | 1.00 | SLC29A1 (1.00) | SLC29A1STAT6 | |
| SCHEMBL5044909 | 0.91 | SLC29A1 (0.91) | SLC29A1STAT6 | |
| SCHEMBL23323472 | 0.88 | SLC29A1 (0.79) | SLC29A1STAT6 | |
| SCHEMBL13688488 | 0.88 | SLC29A1 (0.79) | SLC29A1STAT6 | |
| SCHEMBL27427587 | 0.87 | SLC29A1 (0.76) | SLC29A1STAT6 | |
| SCHEMBL6760626 | 0.86 | SLC29A1 (0.81) | SLC29A1STAT6 | |
| Nitrobenzylmercaptopurine Ribonucleoside SCHEMBL1321676 | 0.86 | SLC29A1 (1.00) | SLC29A1STAT6 | |
| Nitrobenzylmercaptopurine Ribonucleoside SCHEMBL290702 | 0.86 | SLC29A1 (1.00) | SLC29A1STAT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20240226234-A1 | WNT5A PEPTIDES FOR THE TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA | WNTRESEARCH AB (SE) | 2024-07-11 | — | — | US | disclosed |
| EP-4346873-A1 | WNT5A PEPTIDES FOR THE TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA | Wntresearch AB (SE) | 2024-04-10 | — | — | EP | disclosed |
| CN-117500517-A | WNT5A peptides for treating acute myelogenous leukemia | 温特研究公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2022253506-A1 | WNT5A PEPTIDES FOR THE TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA | WNTRESEARCH AB (SE) | 2022-12-08 | — | — | WO | disclosed |
| US-10300049-B2 | Myeloid differentiation inducing agents | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-05-28 | — | — | US | disclosed |
| US-20170000774-A1 | MYELOID DIFFERENTIATION INDUCING AGENTS | CASE WESTERN RESERVE UNIVERSITY | 2017-01-05 | — | — | US | disclosed |
| US-9439894-B2 | Myeloid differentiation inducing agents | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-09-13 | — | — | US | disclosed |
| WO-2015042158-A1 | MYELOID DIFFERENTIATION INDUCING AGENTS | CASE WESTERN RESERVE UNIVERSITY (US) | 2015-03-26 | — | — | WO | disclosed |
| US-8815827-B2 | Myeloid differentiation inducing agents | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-08-26 | — | — | US | disclosed |
| US-20140018383-A1 | MYELOID DIFFERENTIATION INDUCING AGENTS | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-01-16 | — | — | US | disclosed |
| US-20100267656-A1 | MYELOID DIFFERENTIATION INDUCING AGENTS | CASE WESTERN RESERVE UNIVERSITY | 2010-10-21 | — | — | US | disclosed |
| US-20100179312-A1 | CONVERTIBLE NUCLEOSIDE DERIVATIVES | LAKSHMAN MAHESH K | 2010-07-15 | — | — | US | disclosed |
| WO-2008154629-A1 | MYELOID DIFFERENTIATION INDUCING AGENTS | CASE WESTERN RESERVE UNIVERSITY (US) | 2008-12-18 | — | — | WO | disclosed |
| EP-1612210-B1 | New analogs of nitrobenzylthioinosine | GRUENENTHAL GMBH (DE) | 2007-09-26 | — | — | EP | disclosed |
| EP-1761534-A2 | NEW ANALOGS OF NITROBENZYLTHIOINOSINE | Grünenthal GmbH (DE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006002846-A2 | NEW ANALOGS OF NITROBENZYLTHIOINOSINE | Grünenthal GmbH (DE) | 2006-01-12 | — | — | WO | disclosed |
| EP-1612210-A1 | New analogs of nitrobenzylthioinosine | Grünenthal GmbH (DE) | 2006-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179312-A1 | CONVERTIBLE NUCLEOSIDE DERIVATIVES | PNP, NUDT1, NUDT14 | SLC29A1 19/4885STAT6 4656/4885 |
| US-20140018383-A1 | MYELOID DIFFERENTIATION INDUCING AGENTS | MYADM, MCL1, MYD88 | SLC29A1 3318/4885STAT6 19/4885 |
| US-20100267656-A1 | MYELOID DIFFERENTIATION INDUCING AGENTS | MYADM, MCL1, MYD88 | SLC29A1 3096/4885STAT6 16/4885 |
| US-20170000774-A1 | MYELOID DIFFERENTIATION INDUCING AGENTS | MYADM, MCL1, MYD88 | SLC29A1 3318/4885STAT6 19/4885 |
| US-10300049-B2 | Myeloid differentiation inducing agents | MYADM, MCL1, MYD88 | SLC29A1 3318/4885STAT6 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.